Nippon Shinyaku Q1 FY2027: Revenue jumps 24.1% on new drug sales
Revenue
¥49.1B
+24.1%
Full-year forecast
¥200.0B
Operating Profit
¥12.3B
+22.1%
Full-year forecast
¥38.0B
Net Income
¥10.1B
+22.5%
Full-year forecast
¥30.3B
Operating Margin
25.1%
Nippon Shinyaku posted a 24.1% year-on-year increase in revenue to 49,066 million yen for the first quarter of FY2027, driven by strong sales of new drugs Aririda and Fintepla. Operating profit rose 22.1% to 12,311 million yen, while net income attributable to owners of the parent climbed 22.5% to 10,109 million yen, a record first-quarter profit.
Financial Highlights
Revenue rose to 49,066 million yen (+24.1% YoY), reflecting robust demand for new pharmaceutical products. Operating profit reached 12,311 million yen (+22.1%), lifting the operating margin to 25.1%. Net income attributable to owners of the parent came in at 10,109 million yen (+22.5%), marking the highest first-quarter profit on record.
R&D expenses jumped 48.6% to 9,197 million yen as the company advanced its pipeline, while SG&A rose 10.8% to 11,075 million yen but remained well-controlled relative to sales. A foreign exchange gain of 881 million yen also supported the bottom line.
Segment Performance
Pharmaceuticals: Revenue surged 26.6% to 43,256 million yen, with segment profit of 11,163 million yen. The newly launched prostate cancer drug Aririda contributed 3,610 million yen, while Fintepla for epilepsy soared 66.9% to 1,480 million yen. Established products also performed well: Viltepso for Duchenne muscular dystrophy grew 8.5% to 5,637 million yen, and Uptravi for pulmonary hypertension rose 8.6% to 4,750 million yen. Royalty income from industrial property rights increased 11.9% to 12,885 million yen.
Functional Foods: Revenue increased 8.0% to 5,810 million yen, with segment profit of 1,321 million yen, driven by products such as Cattol Cold preparations and Tonalism Beauty.
| Segment | Revenue | Share | Op. Profit | Op. Margin |
|---|---|---|---|---|
| Pharmaceutical | ¥43.3B | 88% | ¥11.2B | 25.8% |
| Functional Foods | ¥5.8B | 12% | ¥1.3B | 22.7% |
Full-Year Outlook
Nippon Shinyaku left its FY2027 full-year forecasts unchanged, targeting revenue of 200,000 million yen (+17.1% vs the prior year), operating profit of 38,000 million yen (+7.1%), and net income of 30,300 million yen (+1.9%). The first-quarter progress stands at 24.5% for revenue and 32.4% for operating profit. The conservative stance likely reflects planned R&D spending of 40,500 million yen and uncertainty over currency movements.
Financial Position and Capital Policy
Total assets declined 1,206 million yen from the prior fiscal year-end to 345,153 million yen, with cash and cash equivalents of 72,699 million yen and zero interest-bearing debt. The equity ratio attributable to owners of the parent rose to 85.6% from 84.2%. Operating cash flow was 1,834 million yen (versus 6,798 million yen a year earlier), largely due to increased trade receivables and tax payments. Investing activities consumed 2,317 million yen, mainly for intangible assets linked to R&D. Free cash flow turned negative, but ample liquidity remains.
Nippon Shinyaku plans to maintain an annual dividend of 124 yen per share (interim 62 yen, year-end 62 yen). The payout ratio is 27.6%, leaving room for future increases. No share buybacks were conducted, and improving capital efficiency is an ongoing challenge.
Risks and Challenges
Nippon Shinyaku faces several risk factors:
- Patent disputes: In the U.S. patent litigation over Viltepso, a jury in May 2026 found Sarepta’s patents valid and Nippon Shinyaku’s invalid. The company views the risk of appeal and damages as limited. Litigation with Capricor over the delamiocel sales agreement is also ongoing.
- Drug price revisions: Radical reforms to Japan’s drug pricing system could impact revenue from major products.
- R&D uncertainty: Many pipeline candidates are still in clinical trials; delays or failures, especially for delamiocel (PDUFA date August 22, 2026), could affect growth plans and short-term share price.
- Foreign exchange: A high ratio of overseas sales means a stronger yen could erode earnings. The first quarter benefited from a weaker yen, but the outlook is uncertain.
R&D and Growth Investments
R&D spending surged 48.6% to 9,197 million yen, representing 18.8% of revenue. Key pipeline updates include:
- Viltolarsen: Exon 53 skipping DMD treatment marketed in Japan and the U.S. The global Phase III CSR has been submitted to the FDA.
- Delamiocel: Seeking accelerated approval in the U.S. for cardiomyopathy. An advisory committee met on July 29, 2026, with a PDUFA date of August 22, 2026. Approval could unlock a major growth opportunity.
- Fintepla: Label expansion into CDKL5 deficiency is in global Phase III; preparation for Phase III in Rett syndrome is underway.
- Gene therapy: RGX-121 (MPS II) is expected to resubmit the BLA in Q2 FY2026 after FDA discussions. RGX-111 (MPS I) remains in clinical development.
These next-generation programs are the key mid- to long-term growth drivers.
Analyst take
Nippon Shinyaku’s first quarter exceeded expectations as the pharmaceutical business benefited from the launch of Aririda and continued momentum of existing products. The ability to hold a 25% operating margin amid a sharp increase in R&D spending is especially impressive. However, near-term events including the delamiocel approval decision and the Viltepso patent suit could swing the stock. The financial foundation is rock-solid, with a debt-free balance sheet and high cash reserves that provide resilience. The key catalysts ahead are delamiocel’s potential approval and progress in the gene therapy pipeline. Domestically, the submission of GA101 for idiopathic nephrosis is also on the horizon; a maturing pipeline should sustain medium-term growth.